Executive Summary : | Trauma remains a significant public health issue becoming the leading cause of death. Human Serum Albumin (HSA) is the prime therapeutic protein administered in the patients suffering from it. Currently, HSA is primarily obtained from the fractionation of collected human blood, which is a limited and unsafe source possessing the risk of contamination by blood derived pathogens. Thus there exists an indispensable need to promote non animal derived rHSA production. Considering the availability of various FDA approved recombinant therapeutics produced in E. colisystem, rHSA production using the same host can be of significant benefit for the desired applications. In this project we are proposing for enhancement of functional rHSA production in the very well-studied, scalable, fast growing and convenient expression host system, i.e. E. coli through recombinant DNA technology. Hence, developing an E. coli based system to prepare immensely important, multi-application oriented recombinant therapeutic protein like HSA is truly important and immensely demand driven. |
Co-PI: | Prof. K. J. Mukherjee, Professor and Dean, Jawahar Lal Nehru University (JNU), New Delhi, Prof. Amit Kumar Dinda, Professor, All India Institute of Medical Sciences (AIIMS), New Delhi |
